Topline data were announced from a phase 3 trial evaluating orforglipron in adults with T2D and inadequate glycemic control with diet and exercise alone.

A daily pill from Eli Lilly lowered blood sugar levels and induced weight loss in people with Type 2 diabetes, the company ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and role in therapy of vildagliptin for the treatment of type 2 diabetes mellitus were reviewed.

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

In high-risk patients, point-of-care capillary HbA1c was superior to venous HbA1c as uptake was double, leading to faster ...

Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled, phase 2 trial.

China: A study published in the journal Endocrine found that blood glucose fluctuations are significantly linked to the risk ...

Testing your blood sugar gives you important information about how well your type 2 diabetes management and treatment plan is working. It lets you see how factors such as food, exercise ...

Orforglipron significantly reduced HbA1c levels by 1.3% (3mg), 1.6% (12mg), and 1.5% (36mg) compared with 0.1% in the placebo arm. Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1 ...